Amicus Therapeutics Inc. kicked off the trading day on 10/10/19 with a price increase of 1.87%, equivalent to $0.14 relative change for the day. Taking a more long-term approach, FOLD had a 52-week range of $7.11 to $14.61. At the time of this article’s publishing, this stock is trading at $7.62 after starting the trading session at $8.00. At the time of writing, this stock’s 50-day Moving Average stands at $9.65, while the 200-day Moving Average of this stock is currently $11.70.
Currently, this company’s share volume is sitting at $6032978, but has maintained average daily volume of $3.93M. This stock has generated an average Year to Date volume of $3.37 million, alongside an average 20-day volume of $4.66 million. This publicly-traded company’s shares outstanding now amounts to $282.84 million, simultaneously with a float of $252.62 million. The organization now has a market capitalization sitting at $2.16 billion.
Amicus Therapeutics Inc.(FOLD) Ownership Data
Now let’s turn our focus to how large-scale investors are behaving with this stock. Amicus Therapeutics Inc.’s current insider ownership accounts for 0.90%. According to the most recent latest insider trade that took place on Sep 11 this organization’s Chairman & CEO exercised an option 20,000 at the rate of 3.82, making the entire transaction hit 76,400 in total value, affecting insider ownership by 770,194. Preceding that transaction, on Sep 11 Company’s Chairman & CEO sold 20,000 at a price of 10.05, making the whole transaction’s value amount to 201,030. This particular insider is now the holder of 750,194 in total.
All together, they are the legal holders of 282.84M shares. If we focus on the top 3 stockholders for this publicly-traded organization, Redmile Group LLC owns 22,792,634 shares, with The Vanguard Group, Inc. in 2nd place owning 21,866,517 shares and Perceptive Advisors LLC in third place with total ownership of 21,509,486 shares.
Amicus Therapeutics Inc. (FOLD) Earnings and Revenue Data
In the latest quarterly report that this company released, which was put into the public domain on 6/29/2019, the organization reported -$0.36 earnings per share (EPS) for the three-month period, surpassing the consensus estimate (set at -$0.33) by -$0.03.
This company achieved a net margin of -336.41 while generating a return on equity of -93.37. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.32 per share during the current fiscal year.
Amicus Therapeutics Inc.’s EPS decrease for this current 12-month fiscal period is -0.50%, and is forecasted to reach -1.13 in the upcoming year.
Additional Trading Performance Indicators
Now turning our attention to the current performance indicators for Amicus Therapeutics Inc., this organization’s Quick Ratio in the last reported quarter now stands at 7.00. The company has managed to achieve an average true range (ATR) of 0.52. Alongside those, its Beta score is 1.53.
Another valuable indicator worth considering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 16.40 for this organization. Plus, this company’s price to book ratio for the last three-month fiscal period reported is 3.02, whereas its price to cash per share for the last quarter landed at 2.04.
In the same vein, FOLD’s Diluted EPS (Earnings per Share) trailing twelve months was posted at -2.17, a figure that is expected to reach -0.33 in the next reported quarter, and analysts expect it will be -1.13 at the market close of one year from today’s date.